115 lines
41 KiB
Text
115 lines
41 KiB
Text
<!DOCTYPE html>
|
|
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" class="no-js no-jr">
|
|
<head>
|
|
<!-- For pinger, set start time and add meta elements. -->
|
|
<script type="text/javascript">var ncbi_startTime = new Date();</script>
|
|
|
|
<!-- Logger begin -->
|
|
<meta name="ncbi_db" content="books">
|
|
<meta name="ncbi_pdid" content="book-part">
|
|
<meta name="ncbi_acc" content="NBK547846">
|
|
<meta name="ncbi_domain" content="livertox">
|
|
<meta name="ncbi_report" content="reader">
|
|
<meta name="ncbi_type" content="fulltext">
|
|
<meta name="ncbi_objectid" content="">
|
|
<meta name="ncbi_pcid" content="/NBK547846/?report=reader">
|
|
<meta name="ncbi_pagename" content="Labetalol - LiverTox - NCBI Bookshelf">
|
|
<meta name="ncbi_bookparttype" content="chapter">
|
|
<meta name="ncbi_app" content="bookshelf">
|
|
<!-- Logger end -->
|
|
|
|
<!--component id="Page" label="meta"/-->
|
|
<script type="text/javascript" src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.boots.min.js"> </script><title>Labetalol - LiverTox - NCBI Bookshelf</title>
|
|
<meta charset="utf-8">
|
|
<meta name="apple-mobile-web-app-capable" content="no">
|
|
<meta name="viewport" content="initial-scale=1,minimum-scale=1,maximum-scale=1,user-scalable=no">
|
|
<meta name="jr-col-layout" content="auto">
|
|
<meta name="jr-prev-unit" content="/books/n/livertox/Kratom/?report=reader">
|
|
<meta name="jr-next-unit" content="/books/n/livertox/Lacosamide/?report=reader">
|
|
<meta name="bk-toc-url" content="/books/n/livertox/?report=toc">
|
|
<meta name="robots" content="INDEX,FOLLOW,NOARCHIVE">
|
|
<meta name="citation_inbook_title" content="LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]">
|
|
<meta name="citation_title" content="Labetalol">
|
|
<meta name="citation_publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases">
|
|
<meta name="citation_date" content="2017/01/15">
|
|
<meta name="citation_pmid" content="31643185">
|
|
<meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK547846/">
|
|
<link rel="schema.DC" href="http://purl.org/DC/elements/1.0/">
|
|
<meta name="DC.Title" content="Labetalol">
|
|
<meta name="DC.Type" content="Text">
|
|
<meta name="DC.Publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases">
|
|
<meta name="DC.Date" content="2017/01/15">
|
|
<meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK547846/">
|
|
<meta name="description" content="Labetalol is an antihypertensive agent with both alpha- and beta-adrenergic receptor blocking activity. Labetalol has been linked to several cases of clinically apparent drug induced liver disease, some of which have been severe and even fatal.">
|
|
<meta name="og:title" content="Labetalol">
|
|
<meta name="og:type" content="book">
|
|
<meta name="og:description" content="Labetalol is an antihypertensive agent with both alpha- and beta-adrenergic receptor blocking activity. Labetalol has been linked to several cases of clinically apparent drug induced liver disease, some of which have been severe and even fatal.">
|
|
<meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK547846/">
|
|
<meta name="og:site_name" content="NCBI Bookshelf">
|
|
<meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png">
|
|
<meta name="twitter:card" content="summary">
|
|
<meta name="twitter:site" content="@ncbibooks">
|
|
<meta name="bk-non-canon-loc" content="/books/n/livertox/Labetalol/?report=reader">
|
|
<link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK547846/">
|
|
<link href="https://fonts.googleapis.com/css?family=Archivo+Narrow:400,700,400italic,700italic&subset=latin" rel="stylesheet" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/libs.min.css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/jr.min.css">
|
|
<meta name="format-detection" content="telephone=no">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books.min.css" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css//books_print.min.css" type="text/css" media="print">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books_reader.min.css" type="text/css">
|
|
<style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace} .first-line-outdent .bk_ref {display: inline} .body-content h2, .body-content .h2 {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list .graphic {display:inline-block !important} .temp-labeled-list img{width:100%}</style>
|
|
|
|
<link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico">
|
|
<meta name="ncbi_phid" content="CE8BE0D77D7D0B610000000000F300CB.m_5">
|
|
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/css/3852956/3849091.css"></head>
|
|
<body>
|
|
<!-- Book content! -->
|
|
|
|
|
|
<div id="jr" data-jr-path="/corehtml/pmc/jatsreader/ptpmc_3.22/"><div class="jr-unsupported"><table class="modal"><tr><td><span class="attn inline-block"></span><br />Your browser does not support the NLM PubReader view.<br />Go to <a href="/pmc/about/pr-browsers/">this page</a> to see a list of supported browsers<br />or return to the <br /><a href="/books/NBK547846/?report=classic">regular view</a>.</td></tr></table></div><div id="jr-ui" class="hidden"><nav id="jr-head"><div class="flexh tb"><div id="jr-tb1"><a id="jr-links-sw" class="hidden" title="Links"><svg xmlns="http://www.w3.org/2000/svg" version="1.1" x="0px" y="0px" viewBox="0 0 70.6 85.3" style="enable-background:new 0 0 70.6 85.3;vertical-align:middle" xml:space="preserve" width="24" height="24">
|
|
<style type="text/css">.st0{fill:#939598;}</style>
|
|
<g>
|
|
<path class="st0" d="M36,0C12.8,2.2-22.4,14.6,19.6,32.5C40.7,41.4-30.6,14,35.9,9.8"></path>
|
|
<path class="st0" d="M34.5,85.3c23.2-2.2,58.4-14.6,16.4-32.5c-21.1-8.9,50.2,18.5-16.3,22.7"></path>
|
|
<path class="st0" d="M34.7,37.1c66.5-4.2-4.8-31.6,16.3-22.7c42.1,17.9,6.9,30.3-16.4,32.5h1.7c-66.2,4.4,4.8,31.6-16.3,22.7 c-42.1-17.9-6.9-30.3,16.4-32.5"></path>
|
|
</g>
|
|
</svg> Books</a></div><div class="jr-rhead f1 flexh"><div class="head"><a href="/books/n/livertox/Kratom/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a></div><div class="body"><div class="t">Labetalol</div><div class="j">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</div></div><div class="tail"><a href="/books/n/livertox/Lacosamide/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div></div><div id="jr-tb2"><a id="jr-bkhelp-sw" class="btn wsprkl hidden" title="Help with NLM PubReader">?</a><a id="jr-help-sw" class="btn wsprkl hidden" title="Settings and typography in NLM PubReader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512" preserveAspectRatio="none"><path d="M462,283.742v-55.485l-29.981-10.662c-11.431-4.065-20.628-12.794-25.274-24.001 c-0.002-0.004-0.004-0.009-0.006-0.013c-4.659-11.235-4.333-23.918,0.889-34.903l13.653-28.724l-39.234-39.234l-28.72,13.652 c-10.979,5.219-23.68,5.546-34.908,0.889c-0.005-0.002-0.01-0.003-0.014-0.005c-11.215-4.65-19.933-13.834-24-25.273L283.741,50 h-55.484l-10.662,29.981c-4.065,11.431-12.794,20.627-24.001,25.274c-0.005,0.002-0.009,0.004-0.014,0.005 c-11.235,4.66-23.919,4.333-34.905-0.889l-28.723-13.653l-39.234,39.234l13.653,28.721c5.219,10.979,5.545,23.681,0.889,34.91 c-0.002,0.004-0.004,0.009-0.006,0.013c-4.649,11.214-13.834,19.931-25.271,23.998L50,228.257v55.485l29.98,10.661 c11.431,4.065,20.627,12.794,25.274,24c0.002,0.005,0.003,0.01,0.005,0.014c4.66,11.236,4.334,23.921-0.888,34.906l-13.654,28.723 l39.234,39.234l28.721-13.652c10.979-5.219,23.681-5.546,34.909-0.889c0.005,0.002,0.01,0.004,0.014,0.006 c11.214,4.649,19.93,13.833,23.998,25.271L228.257,462h55.484l10.595-29.79c4.103-11.538,12.908-20.824,24.216-25.525 c0.005-0.002,0.009-0.004,0.014-0.006c11.127-4.628,23.694-4.311,34.578,0.863l28.902,13.738l39.234-39.234l-13.66-28.737 c-5.214-10.969-5.539-23.659-0.886-34.877c0.002-0.005,0.004-0.009,0.006-0.014c4.654-11.225,13.848-19.949,25.297-24.021 L462,283.742z M256,331.546c-41.724,0-75.548-33.823-75.548-75.546s33.824-75.547,75.548-75.547 c41.723,0,75.546,33.824,75.546,75.547S297.723,331.546,256,331.546z"></path></svg></a><a id="jr-fip-sw" class="btn wsprkl hidden" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-rtoc-sw" class="btn wsprkl hidden" title="Table of Contents"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,20h10v8H20V20zM36,20h44v8H36V20zM20,37.33h10v8H20V37.33zM36,37.33h44v8H36V37.33zM20,54.66h10v8H20V54.66zM36,54.66h44v8H36V54.66zM20,72h10v8 H20V72zM36,72h44v8H36V72z"></path></svg></a></div></div></nav><nav id="jr-dash" class="noselect"><nav id="jr-dash" class="noselect"><div id="jr-pi" class="hidden"><a id="jr-pi-prev" class="hidden" title="Previous page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a><div class="pginfo">Page <i class="jr-pg-pn">0</i> of <i class="jr-pg-lp">0</i></div><a id="jr-pi-next" class="hidden" title="Next page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div><div id="jr-is-tb"><a id="jr-is-sw" class="btn wsprkl hidden" title="Switch between Figures/Tables strip and Progress bar"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><rect x="10" y="40" width="20" height="20"></rect><rect x="40" y="40" width="20" height="20"></rect><rect x="70" y="40" width="20" height="20"></rect></svg></a></div><nav id="jr-istrip" class="istrip hidden"><a id="jr-is-prev" href="#" class="hidden" title="Previous"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M80,40 60,65 80,90 70,90 50,65 70,40z M50,40 30,65 50,90 40,90 20,65 40,40z"></path><text x="35" y="25" textLength="60" style="font-size:25px">Prev</text></svg></a><a id="jr-is-next" href="#" class="hidden" title="Next"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,40 40,65 20,90 30,90 50,65 30,40z M50,40 70,65 50,90 60,90 80,65 60,40z"></path><text x="15" y="25" textLength="60" style="font-size:25px">Next</text></svg></a></nav><nav id="jr-progress"></nav></nav></nav><aside id="jr-links-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">NCBI Bookshelf</div></div><div class="cnt lol f1"><a href="/books/">Home</a><a href="/books/browse/">Browse All Titles</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://www.facebook.com/sharer/sharer.php?u=https://www.ncbi.nlm.nih.gov/books/NBK547846/"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24" preserveAspectRatio="none"><g><path d="M 17.996,32L 12,32 L 12,16 l-4,0 l0-5.514 l 4-0.002l-0.006-3.248C 11.993,2.737, 13.213,0, 18.512,0l 4.412,0 l0,5.515 l-2.757,0 c-2.063,0-2.163,0.77-2.163,2.209l-0.008,2.76l 4.959,0 l-0.585,5.514L 18,16L 17.996,32z"></path></g></svg> Share on Facebook</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://twitter.com/intent/tweet?url=https://www.ncbi.nlm.nih.gov/books/NBK547846/&text=Labetalol"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24"><g><path d="M 32,6.076c-1.177,0.522-2.443,0.875-3.771,1.034c 1.355-0.813, 2.396-2.099, 2.887-3.632 c-1.269,0.752-2.674,1.299-4.169,1.593c-1.198-1.276-2.904-2.073-4.792-2.073c-3.626,0-6.565,2.939-6.565,6.565 c0,0.515, 0.058,1.016, 0.17,1.496c-5.456-0.274-10.294-2.888-13.532-6.86c-0.565,0.97-0.889,2.097-0.889,3.301 c0,2.278, 1.159,4.287, 2.921,5.465c-1.076-0.034-2.088-0.329-2.974-0.821c-0.001,0.027-0.001,0.055-0.001,0.083 c0,3.181, 2.263,5.834, 5.266,6.438c-0.551,0.15-1.131,0.23-1.73,0.23c-0.423,0-0.834-0.041-1.235-0.118 c 0.836,2.608, 3.26,4.506, 6.133,4.559c-2.247,1.761-5.078,2.81-8.154,2.81c-0.53,0-1.052-0.031-1.566-0.092 c 2.905,1.863, 6.356,2.95, 10.064,2.95c 12.076,0, 18.679-10.004, 18.679-18.68c0-0.285-0.006-0.568-0.019-0.849 C 30.007,8.548, 31.12,7.392, 32,6.076z"></path></g></svg> Share on Twitter</a></div></aside><aside id="jr-rtoc-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Table of Content</div></div><div class="cnt lol f1"><a href="/books/n/livertox/?report=reader">Title Information</a><a href="/books/n/livertox/toc/?report=reader">Table of Contents Page</a></div></aside><aside id="jr-help-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Settings</div></div><div class="cnt f1"><div id="jr-typo-p" class="typo"><div><a class="sf btn wsprkl">A-</a><a class="lf btn wsprkl">A+</a></div><div><a class="bcol-auto btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 200 100" preserveAspectRatio="none"><text x="10" y="70" style="font-size:60px;font-family: Trebuchet MS, ArialMT, Arial, sans-serif" textLength="180">AUTO</text></svg></a><a class="bcol-1 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M15,25 85,25zM15,40 85,40zM15,55 85,55zM15,70 85,70z"></path></svg></a><a class="bcol-2 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M5,25 45,25z M55,25 95,25zM5,40 45,40z M55,40 95,40zM5,55 45,55z M55,55 95,55zM5,70 45,70z M55,70 95,70z"></path></svg></a></div></div><div class="lol"><a class="" href="/books/NBK547846/?report=classic">Switch to classic view</a><a href="/books/NBK547846/pdf/Bookshelf_NBK547846.pdf">PDF (93K)</a><a href="/books/NBK547846/?report=printable">Print View</a></div></div></aside><aside id="jr-bkhelp-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Help</div></div><div class="cnt f1 lol"><a id="jr-helpobj-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/help.xml" href="">Help</a><a href="mailto:info@ncbi.nlm.nih.gov?subject=PubReader%20feedback%20%2F%20NBK547846%20%2F%20sid%3ACE8B5AF87C7FFCB1_0191SID%20%2F%20phid%3ACE8BE0D77D7D0B610000000000F300CB.4">Send us feedback</a><a id="jr-about-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/about.xml" href="">About PubReader</a></div></aside><aside id="jr-objectbox" class="thidden hidden"><div class="jr-objectbox-close wsprkl">✘</div><div class="jr-objectbox-inner cnt"><div class="jr-objectbox-drawer"></div></div></aside><nav id="jr-pm-left" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Previous Page</text></svg></nav><nav id="jr-pm-right" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Next Page</text></svg></nav><nav id="jr-fip" class="hidden"><nav id="jr-fip-term-p"><input type="search" placeholder="search this page" id="jr-fip-term" autocorrect="off" autocomplete="off" /><a id="jr-fip-mg" class="wsprkl btn" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-fip-done" class="wsprkl btn" title="Dismiss find">✘</a></nav><nav id="jr-fip-info-p"><a id="jr-fip-prev" class="wsprkl btn" title="Jump to previuos match">◀</a><button id="jr-fip-matches">no matches yet</button><a id="jr-fip-next" class="wsprkl btn" title="Jump to next match">▶</a></nav></nav></div><div id="jr-epub-interstitial" class="hidden"></div><div id="jr-content"><article data-type="main"><div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><div class="fm-sec"><h1 id="_NBK547846_"><span class="title" itemprop="name">Labetalol</span></h1><p class="fm-aai"><a href="#_NBK547846_pubdet_">Publication Details</a></p></div></div><div class="body-content whole_rhythm" itemprop="text"><div id="Labetalol.OVERVIEW"><h2 id="_Labetalol_OVERVIEW_">OVERVIEW</h2><div id="Labetalol.Introduction"><h3>Introduction</h3><p>Labetalol is an antihypertensive agent with both alpha- and beta-adrenergic receptor blocking activity. Labetalol has been linked to several cases of clinically apparent drug induced liver disease, some of which have been severe and even fatal.</p></div><div id="Labetalol.Background"><h3>Background</h3><p>Labetalol (la bayt' a lol) is a unique antihypertensive agent that has both alpha- and beta-adrenergic receptor blocking activity. The beta-blockade is nonselective, acting on both beta-1 and beta-2 adrenergic receptors. Beta-1 adrenergic blockade reduces the heart rate and myocardial contractility by slowing the AV conduction and suppressing automaticity. Beta-2 blockade affects peripheral vascular resistance and can cause bronchospasm and hypoglycemia. The alpha blockade is largely directed at the alpha-1 receptors and leads to relaxation of arterial smooth muscle and vasodilation. Labetalol was approved for use in the United States in 1984 and currently more than 2 million prescriptions are filled yearly. Current indications for labetalol are in the therapy of hypertension alone or in combination with other agents. Parenteral forms of labetalol are indicated for therapy of hypertensive emergencies, severe hypertension and pheochromocytoma. Labetalol is available in tablets of 100, 200 and 300 mg in generic formulations and under the trade name Trandate. Parenteral formulations for intravenous administration are also available. The typical oral dose of labetalol in adults is 100 mg twice daily initially with subsequent dose adjustments based upon clinical response and tolerance to a range of 200 to 1200 mg daily. Common side effects include bradycardia, hypotension, fatigue, dizziness, orthostatic hypotension, depression, memory loss, impotence, weight gain and diarrhea. As with all beta-blockers, sudden withdrawal can trigger rebound hypertension.</p></div><div id="Labetalol.Hepatotoxicity"><h3>Hepatotoxicity</h3><p>Labetalol therapy has been associated with mild-to-moderate elevations of serum aminotransferase levels in up to 8% of patients, a rate far higher than with other beta-blockers. These elevations, however, are usually transient, not associated with symptoms, and can resolve even with continuation of therapy. Idiosyncratic, clinically apparent liver injury from labetalol is rare, but several instances have been reported as isolated case reports as well as in case series. The liver injury typically arises after 4 to 16 weeks of therapy and the pattern of serum enzyme elevations is usually hepatocellular with an acute hepatitis-like onset and course. Immunoallergic features (rash, fever, eosinophilia) are uncommon as is autoantibody formation. While most cases resolve rapidly once labetalol is stopped, there have been several instances of acute liver failure and death or need for emergency liver transplantation associated with labetalol use, particularly if there is a delay in its discontinuation. Labetalol is the beta-blocker with the highest apparent risk for causing clinically apparent liver injury.</p><p>Likelihood score: C (probable although rare cause of clinically apparent liver injury).</p></div><div id="Labetalol.Mechanism_of_Injury"><h3>Mechanism of Injury</h3><p>The mechanism of labetalol hepatic injury is unknown, but it believed to be due to metabolic idiosyncratic disposition of the agent, which is known to be extensively metabolized in the liver. There is little evidence for hypersensitivity as the cause of injury but it is likely to be due to an idiosyncractic rather than an intrinsic reaction.</p></div><div id="Labetalol.Outcome_and_Management"><h3>Outcome and Management</h3><p>Severity ranges from minimal and transient ALT elevations to clinically apparent acute hepatitis with jaundice to acute liver failure and death or need for liver transplantation. No instances of chronic hepatic injury or vanishing bile duct syndrome attributable to labetalol have been reported. Rechallenge is usually followed by recurrence of liver injury and should be avoided. There is little information on whether there is cross reactivity of the liver injury with other beta-blockers and patients who are switched to other agents should be carefully monitored.</p><p>References to the safety and potential hepatotoxicity of labetalol are provided in the overview on Beta-Adrenergic Receptor Antagonists, last updated June 2019.</p><p>Drug Class: <a href="/books/n/livertox/Betablockers/?report=reader">Beta-Adrenergic Receptor Antagonists</a></p></div></div><div id="Labetalol.CASE_REPORT"><h2 id="_Labetalol_CASE_REPORT_">CASE REPORT</h2><div id="Labetalol.Case_1._Labetalol_induced_acut"><h3>Case 1. Labetalol induced acute liver injury.</h3><p>[Modified from: Douglas DD, Yang RD, Jensen P, Thiele DL. Fatal labetalol-induced hepatic injury. Am J Med 1989; 87: 235-6. <a href="https://www.ncbi.nlm.nih.gov/pubmed/2757062" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PubMed Citation</a>]</p><p>A 63 year old woman developed nausea and dark urine approximately 3 months after starting labetalol (200 mg daily) for hypertension. She had no previous history of liver disease, jaundice, or risk factors for viral hepatitis. She was not taking any other medications and denied alcohol abuse. Laboratory testing showed serum bilirubin of 3.6 mg/dL and serum enzyme elevations typical of acute hepatitis (Table). She was negative for serological markers for hepatitis A and B. No diagnosis was made, and she was given another prescription for labetalol, but evidently stopped taking it on her own. Over the next few weeks she recovered, but was then lost to follow up for at least 6 months. When seen again, she had normal liver tests and was hypertensive. Labetalol was restarted. Two months later she developed anorexia and the following month presented with jaundice and serum bilirubin of 3.1 mg/dL. Labetalol was stopped and she was monitored closely. Tests for viral hepatitis were again negative as were routine autoantibodies. Abdominal ultrasound showed gallstones, but no evidence of biliary obstruction. There was mild ascites. Her liver condition worsened, and she developed progressive hepatic failure and died approximately 6 weeks after stopping labetalol for the second time. Autopsy showed a shrunken liver with extensive multilobular collapse with broad bands of fibrosis.</p><div id="Labetalol.Key_Points"><h4>Key Points</h4><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figLabetalolT1"><a href="/books/NBK547846/table/Labetalol.T1/?report=objectonly" target="object" title="Table" class="img_link icnblk_img" rid-ob="figobLabetalolT1"><img class="small-thumb" src="/corehtml/pmc/css/bookshelf/2.26/img/table-icon.gif" alt="Table Icon" /></a><div class="icnblk_cntnt"><h4 id="Labetalol.T1"><a href="/books/NBK547846/table/Labetalol.T1/?report=objectonly" target="object" rid-ob="figobLabetalolT1">Table</a></h4></div></div></div><div id="Labetalol.Laboratory_Values"><h4>Laboratory Values</h4><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figLabetalolT2"><a href="/books/NBK547846/table/Labetalol.T2/?report=objectonly" target="object" title="Table" class="img_link icnblk_img" rid-ob="figobLabetalolT2"><img class="small-thumb" src="/corehtml/pmc/css/bookshelf/2.26/img/table-icon.gif" alt="Table Icon" /></a><div class="icnblk_cntnt"><h4 id="Labetalol.T2"><a href="/books/NBK547846/table/Labetalol.T2/?report=objectonly" target="object" rid-ob="figobLabetalolT2">Table</a></h4></div></div><p>* Converted from μKat/L and μmol/L.</p></div><div id="Labetalol.Comment"><h4>Comment</h4><p>This patient developed an acute hepatitis-like clinical picture 3 months after starting labetalol. Despite the lack of a suitable diagnosis, labetalol was not discontinued, although the patient evidently stopped taking it on her own and did not return for further management of her hypertension. When seen 6 months later, labetalol was restarted and a similar clinical syndrome arose 2 to 3 months later, but with a progressive and ultimately fatal course. Labetalol has been implicated in at least a dozen cases of acute liver injury with a predominantly hepatocellular pattern of enzyme elevations, a latency period of 2 to 16 weeks, and fatal outcome or emergency liver transplantation in several instances. In contrast, most cases of clinically apparent liver injury due to other beta-blockers have had a somewhat shorter latency period (2 to 12 weeks) and a milder course and outcome. Acute liver injury has also been described with dilevolol, which is one of the 4 stereoisomers of labetalol that has predominantly beta-adrenergic blocking activity.</p></div></div></div><div id="Labetalol.PRODUCT_INFORMATION"><h2 id="_Labetalol_PRODUCT_INFORMATION_">PRODUCT INFORMATION</h2><div id="Labetalol.BPI" class="box boxed-text-box whole_rhythm hide-overflow"><p>
|
|
<b>REPRESENTATIVE TRADE NAMES</b>
|
|
</p><p>Labetalol – Generic, Trandate®</p><p>
|
|
<b>DRUG CLASS</b>
|
|
</p><p>Beta-Adrenergic Receptor Antagonists</p><p>
|
|
<a href="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=labetalol" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">COMPLETE LABELING</a>
|
|
</p><p>Product labeling at DailyMed, National Library of Medicine, NIH</p></div></div><div id="Labetalol.CHEMICAL_FORMULA_AND_STRUCTURE"><h2 id="_Labetalol_CHEMICAL_FORMULA_AND_STRUCTURE_">CHEMICAL FORMULA AND STRUCTURE</h2><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figLabetalolT3"><a href="/books/NBK547846/table/Labetalol.T3/?report=objectonly" target="object" title="Table" class="img_link icnblk_img" rid-ob="figobLabetalolT3"><img class="small-thumb" src="/corehtml/pmc/css/bookshelf/2.26/img/table-icon.gif" alt="Table Icon" /></a><div class="icnblk_cntnt"><h4 id="Labetalol.T3"><a href="/books/NBK547846/table/Labetalol.T3/?report=objectonly" target="object" rid-ob="figobLabetalolT3">Table</a></h4></div></div></div><div id="bk_toc_contnr"></div></div></div><div class="fm-sec"><h2 id="_NBK547846_pubdet_">Publication Details</h2><h3>Publication History</h3><p class="small">Last Update: <span itemprop="dateModified">January 15, 2017</span>.</p><h3>Copyright</h3><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright Notice</a></div></div><h3>Publisher</h3><p><a href="https://www.niddk.nih.gov/" ref="pagearea=page-banner&targetsite=external&targetcat=link&targettype=publisher">National Institute of Diabetes and Digestive and Kidney Diseases</a>, Bethesda (MD)</p><h3>NLM Citation</h3><p>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Labetalol. [Updated 2017 Jan 15].<span class="bk_cite_avail"></span></p></div><div class="small-screen-prev"><a href="/books/n/livertox/Kratom/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a></div><div class="small-screen-next"><a href="/books/n/livertox/Lacosamide/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div></article><article data-type="table-wrap" id="figobLabetalolT1"><div id="Labetalol.T1" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK547846/table/Labetalol.T1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Labetalol.T1_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="vertical-align:top;">Medication:</td><td rowspan="1" colspan="1" style="vertical-align:top;">Labetalol (200 mg daily)</td></tr><tr><td rowspan="1" colspan="1" style="vertical-align:top;">Pattern:</td><td rowspan="1" colspan="1" style="vertical-align:top;">Hepatocellular (R=23)</td></tr><tr><td rowspan="1" colspan="1" style="vertical-align:top;">Severity:</td><td rowspan="1" colspan="1" style="vertical-align:top;">2+ (initially); 5+ (upon reexposure); fatal</td></tr><tr><td rowspan="1" colspan="1" style="vertical-align:top;">Latency:</td><td rowspan="1" colspan="1" style="vertical-align:top;">3 months</td></tr><tr><td rowspan="1" colspan="1" style="vertical-align:top;">Recovery:</td><td rowspan="1" colspan="1" style="vertical-align:top;">1 month after initial episode</td></tr><tr><td rowspan="1" colspan="1" style="vertical-align:top;">Other medications:</td><td rowspan="1" colspan="1" style="vertical-align:top;">None</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobLabetalolT2"><div id="Labetalol.T2" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK547846/table/Labetalol.T2/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Labetalol.T2_lrgtbl__"><table><thead><tr><th id="hd_h_Labetalol.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Weeks After Starting</th><th id="hd_h_Labetalol.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Weeks After Stopping</th><th id="hd_h_Labetalol.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">AST* (U/L)</th><th id="hd_h_Labetalol.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Alk P* (U/L)</th><th id="hd_h_Labetalol.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">Bilirubin* (mg/dL)</th><th id="hd_h_Labetalol.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">Other</th></tr></thead><tbody><tr><td headers="hd_h_Labetalol.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">0 (pre)</td><td headers="hd_h_Labetalol.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">0</td><td headers="hd_h_Labetalol.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">11</td><td headers="hd_h_Labetalol.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">92</td><td headers="hd_h_Labetalol.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">0.3</td><td headers="hd_h_Labetalol.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr><tr><td headers="hd_h_Labetalol.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">12</td><td headers="hd_h_Labetalol.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">0</td><td headers="hd_h_Labetalol.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">1253</td><td headers="hd_h_Labetalol.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">205</td><td headers="hd_h_Labetalol.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">3.6</td><td headers="hd_h_Labetalol.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">Labetolol stopped</td></tr><tr><td headers="hd_h_Labetalol.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">14</td><td headers="hd_h_Labetalol.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">2 weeks</td><td headers="hd_h_Labetalol.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">247</td><td headers="hd_h_Labetalol.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">150</td><td headers="hd_h_Labetalol.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">1.5</td><td headers="hd_h_Labetalol.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr><tr><td headers="hd_h_Labetalol.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">16</td><td headers="hd_h_Labetalol.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">4 weeks</td><td headers="hd_h_Labetalol.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">37</td><td headers="hd_h_Labetalol.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">111</td><td headers="hd_h_Labetalol.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">0.4</td><td headers="hd_h_Labetalol.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr><tr><td headers="hd_h_Labetalol.T2_1_1_1_1 hd_h_Labetalol.T2_1_1_1_2 hd_h_Labetalol.T2_1_1_1_3 hd_h_Labetalol.T2_1_1_1_4 hd_h_Labetalol.T2_1_1_1_5 hd_h_Labetalol.T2_1_1_1_6" colspan="6" rowspan="1" style="vertical-align:top;">Patient was lost to follow up for 6 months</td></tr><tr><td headers="hd_h_Labetalol.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">0</td><td headers="hd_h_Labetalol.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">0</td><td headers="hd_h_Labetalol.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">13</td><td headers="hd_h_Labetalol.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">117</td><td headers="hd_h_Labetalol.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">0.3</td><td headers="hd_h_Labetalol.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">Labetalol restarted</td></tr><tr><td headers="hd_h_Labetalol.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">13</td><td headers="hd_h_Labetalol.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">0</td><td headers="hd_h_Labetalol.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">1007</td><td headers="hd_h_Labetalol.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">172</td><td headers="hd_h_Labetalol.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">3.1</td><td headers="hd_h_Labetalol.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr><tr><td headers="hd_h_Labetalol.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">16</td><td headers="hd_h_Labetalol.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">3</td><td headers="hd_h_Labetalol.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">582</td><td headers="hd_h_Labetalol.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">283</td><td headers="hd_h_Labetalol.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">9.5</td><td headers="hd_h_Labetalol.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr><tr><td headers="hd_h_Labetalol.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">17</td><td headers="hd_h_Labetalol.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">4</td><td headers="hd_h_Labetalol.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">402</td><td headers="hd_h_Labetalol.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">315</td><td headers="hd_h_Labetalol.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">11.3</td><td headers="hd_h_Labetalol.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr><tr><td headers="hd_h_Labetalol.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">18</td><td headers="hd_h_Labetalol.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">5</td><td headers="hd_h_Labetalol.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">303</td><td headers="hd_h_Labetalol.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">321</td><td headers="hd_h_Labetalol.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">12.0</td><td headers="hd_h_Labetalol.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr><tr><td headers="hd_h_Labetalol.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">19</td><td headers="hd_h_Labetalol.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">6</td><td headers="hd_h_Labetalol.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">225</td><td headers="hd_h_Labetalol.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">266</td><td headers="hd_h_Labetalol.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">16.8</td><td headers="hd_h_Labetalol.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">Death from liver failure</td></tr><tr><td headers="hd_h_Labetalol.T2_1_1_1_1 hd_h_Labetalol.T2_1_1_1_2" colspan="2" rowspan="1" style="vertical-align:top;">
|
|
<b>Normal Values</b>
|
|
</td><td headers="hd_h_Labetalol.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<b><40</b>
|
|
</td><td headers="hd_h_Labetalol.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<b><110</b>
|
|
</td><td headers="hd_h_Labetalol.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<b><1.2</b>
|
|
</td><td headers="hd_h_Labetalol.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr></tbody></table></div></div></article><article data-type="boxed-text" id="figobLabetalolBPI"><div id="Labetalol.BPI" class="box boxed-text-box whole_rhythm hide-overflow"><p>
|
|
<b>REPRESENTATIVE TRADE NAMES</b>
|
|
</p><p>Labetalol – Generic, Trandate®</p><p>
|
|
<b>DRUG CLASS</b>
|
|
</p><p>Beta-Adrenergic Receptor Antagonists</p><p>
|
|
<a href="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=labetalol" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">COMPLETE LABELING</a>
|
|
</p><p>Product labeling at DailyMed, National Library of Medicine, NIH</p></div></article><article data-type="table-wrap" id="figobLabetalolT3"><div id="Labetalol.T3" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK547846/table/Labetalol.T3/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Labetalol.T3_lrgtbl__"><table><thead><tr><th id="hd_h_Labetalol.T3_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">DRUG</th><th id="hd_h_Labetalol.T3_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">CAS REGISTRY NUMBER</th><th id="hd_h_Labetalol.T3_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">MOLECULAR FORMULA</th><th id="hd_h_Labetalol.T3_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">STRUCTURE</th></tr></thead><tbody><tr><td headers="hd_h_Labetalol.T3_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Labetalol</td><td headers="hd_h_Labetalol.T3_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="https://pubchem.ncbi.nlm.nih.gov/substance/134998768" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubchem">36894-69-6</a>
|
|
</td><td headers="hd_h_Labetalol.T3_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">C19-H24-N2-O3</td><td headers="hd_h_Labetalol.T3_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<div class="graphic"><img src="/books/NBK547846/bin/Labetalol_Structure.jpg" alt="Labetalol Chemical Structure" /></div>
|
|
</td></tr></tbody></table></div></div></article></div><div id="jr-scripts"><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/libs.min.js"> </script><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.min.js"> </script></div></div>
|
|
|
|
|
|
|
|
|
|
<!-- Book content -->
|
|
|
|
<script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js"> </script>
|
|
|
|
|
|
<!-- CE8B5AF87C7FFCB1_0191SID /projects/books/PBooks@9.11 portal104 v4.1.r689238 Tue, Oct 22 2024 16:10:51 -->
|
|
<span id="portal-csrf-token" style="display:none" data-token="CE8B5AF87C7FFCB1_0191SID"></span>
|
|
|
|
<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/js/3968615.js" snapshot="books"></script></body>
|
|
</html>
|